



Partial Interdigitation of Lipid Bilayers

Journal:	<i>International Journal of Quantum Chemistry</i>
Manuscript ID:	Draft
Wiley - Manuscript type:	Special Issue Article
Date Submitted by the Author:	
Complete List of Authors:	Mavromoustakos, Thomas; National and Kapodistrian University of Athens, Department of Chemistry Petros, Chatzigeorgiou; National and Kapodistrian University of Athens, Chemistry Department Koukoulitsa, Catherine; National and Kapodistrian University of Athens, Chemistry Department Durdagi, Serdar; Institute of Biocomplexity and Informatics, Department of Biological Sciences
Keywords:	Partial Interdigitation, Lipid Bilayers, DSC, Raman Spectroscopy, MD Simulation



Partial Interdigitation of Lipid Bilayers

Thomas Mavromoustakos¹, Petros Chatzigeorgiou², Catherine Koukoulitsa¹,
Serdar Durdagi³

¹National Kapodistrian University of Athens, Chemistry Department, Organic
Chemistry Laboratory, Zographou 15771, Panepistimioupolis, Athens, Greece.

²National Kapodistrian University of Athens, Chemistry Department, Physical
Chemistry Laboratory, Zographou 15771, Panepistimioupolis, Athens, Greece.

³University of Calgary, Department of Biological Sciences, Institute of
Biocomplexity and Informatics, 2500 University Drive, NW, T2N 1N4, Calgary,
Alberta, Canada.

Abstract

A methodology has been developed to detect partial interdigitation of lipid bilayers when a bioactive molecule is intercalated between the polar, interface or hydrophobic segments. This methodology uses the easily accessible Differential Scanning Calorimetry (DSC) technique as a screening one and the increase of ΔH due to the incorporated drug in lipid bilayers as a diagnostic thermodynamic parameter. The combination of x-ray diffraction and Raman spectroscopy complement and confirm the provided by DSC information as it is shown in three classes of molecules, namely AT₁ antagonists, vinca alkaloids and anesthetic steroids. For the two classes of molecules AT₁ antagonists and vinca alkaloids their presence in lipid bilayers result in the increase of ΔH and it is accompanied by increase of *trans:gauche* ratio and decrease of d-spacing as depicted by Raman Spectroscopy and small angle x-ray diffraction correspondingly, confirming the predictive ability of DSC experiments. When an anesthetic steroid is incorporated in lipid bilayers neither increase of ΔH was observed nor decrease of d-spacing confirming again the DSC results which show absence of partial interdigitation of this class of molecules. Molecular dynamics simulations have been carried out for a representative system (MMK3 ligands at DMPC lipid bilayer) and results confirmed the experimental findings. Change of distance at z-axis of oxygen atoms at head group of lipid molecule has been measured throughout the simulations. Statistical analysis has shown ~8.8 Å interdigitation. Derived computational results are encouraging and can be performed to another ligand/lipid system. The development of a theoretical methodology will lead to advance the field and save a valuable time and effort.

Abbreviations: MD, Molecular Dynamics; VMD, Visual Molecular Dynamics; SAXS, Small angle X-ray scattering; PSPS, Position-sensitive proportional counting;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DSC, Differential Scanning Calorimetry; GROMACS, GRONingen MACHine for Chemical Simulations; GROMOS, GRONingen MOlecular Simulation, LINCS, LINear Constraint Solver; Alphaxalone, 5 α -pregnan-16-en-3 α -ol-11,20-dione; Δ^{16} -alphaxalone, 5 α -pregn-16-en-3 α -ol-11,20-dione; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine. Losartan, (2-butyl-4-chloro-1-([2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl)-1*H*-imidazol-5-yl)methanol; MMK3, (5*S*)-1-benzyl-5-(1*H*-benzimidazol-1-yl-methyl)-2-pyrrolidinone; Vinblastine, dimethyl (2 β ,3 β ,4 β ,5 α ,12 β ,19 α)-15-[(5*S*,9*S*)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2*H*-3,7-methanoazacycloundecino [5,4-*b*]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydrospidospermidine-3,4 dicarboxylate; Vincristine, methyl (1*R*,9*R*,10*S*,11*R*,12*R*,19*R*)-11-(acetyloxy)-12-ethyl-4-[(13*S*,15*S*,17*S*)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11 diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraene-10-carboxylate;

Introduction

There is a great literature evidence pointing out that interdigitated phase can be induced by bioactive organic molecules when they are incorporated in the lipid bilayers. This interdigitation can be characterized as partial, mixed or full depending on the extend of the alkyl chain penetration from one alkyl chain to the opposite [1] [Figure 1]. Such molecules include ethanol, benzyl alcohol, vinblastine, vinorelbine, atropine, tetracaine, labdanes, chlorpromazine, MMK3 etc [2-18] [Figure 2].

In a previous publications we have pointed out that partial interdigitation can occur in fluid phase and that this interdigitation is caused by molecules characterized as: (i) amphiphilic; (ii) preferably bulky; (iii) act on the interface; and (iv) are not very long. Cholesterol is found to break the interdigitation effect since it is very long and it does not allow the alkyl chains of the two layers to interdigitate [6,8,9].

To detect the interdigitation in the fluid phase, at least three physical chemical techniques are used in our laboratory: (a) x-ray diffraction experiments using as a diagnostic factor the d-spacing (lamellar periodic distance between the bilayers). However, decrease of the d-spacing in the presence of bioactive material can be attributed to two reasons: (i) due to mesomorphic changes and (ii) interdigitation effect. It is well known that when phospholipids undergo a phase transition from the gel to the liquid crystalline phase, conformational changes occur in the alkyl

1
2
3 chain, thus all *trans* conformations are transformed to *gauche* conformations
4 (kinks) that shorten the d-spacing. (b) Raman spectroscopy is suitable through
5
6 measuring the *gauche:trans* ratio and the intermolecular interactions of the
7
8 opposite acyl chains in the fluid phase to confirm if the decrease of the d-spacing
9
10 is due to mesomorphic changes or interdigitation effects. (c) Differential Scanning
11
12 Calorimetry (DSC) is used also as a technique for detecting the interdigitation.
13
14 Increase of the enthalpy change of the melting curve in the thermal scans due to
15
16 incorporation of the drug is interpreted as a sign of interdigitation.
17
18
19
20
21

22 More specifically: DSC is a suitable relatively inexpensive technique to study
23
24 drug:membrane interactions. It has been extensively used to study the thermal
25
26 properties of phospholipid bilayers [6,8,9 and references therein]. For example,
27
28 the studies of mesomorphic changes of dipalmitoylphosphatidylcholine bilayers
29
30 have shown that this exists in the gel phase for temperatures lower than 35 °C, and
31
32 in the liquid crystalline phase for temperatures higher than 42 °C. The transition is
33
34 accompanied by several structural changes in the lipid molecules as well as
35
36 systematic alterations in the bilayer geometry, but the most prominent feature is
37
38 the *gauche:trans* isomerization taking place in the acyl conformation. The average
39
40 number of *gauche* conformers indicates the effective fluidity, which depends on
41
42 perturbations due to the presence of a drug molecule intercalating between the
43
44 lipids. Various parameters have been used for interpreting the phase transition
45
46 such as the maximum of the phase transition T_m , the onset of the phase transition
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 T_{onset} and the area of the phase transition which represents ΔH . Among these, ΔH ,
4
5 as it is already mentioned, is the most diagnostic for showing the interdigitation
6
7 effect. Increase of ΔH is interpreted as cause of interdigitation effect. Thus,
8
9 integration of the thermal scans containing phospholipid bilayers alone and drug
10
11 incorporation will show us the possible interdigitation effect. However, DSC
12
13 diagnostic parameter ΔH alone can not show unambiguously the interdigitation
14
15 effect. Other techniques are used as complementary, to confirm this effect.
16
17

18
19
20 Raman Spectroscopy is one of those techniques that complement DSC data. It is a
21
22 valuable spectroscopic technique not yet fully explored in the field of
23
24 drug:membrane interactions. Information concerning the intramolecular
25
26 interactions in the lipid molecules due to *gauche:trans* isomerization as well as the
27
28 intermolecular acyl-chain interactions of the lipids in the bilayer can be retrieved
29
30 through Raman spectroscopy. In particular, the intensity of certain bands (2850
31
32 cm^{-1} , 2880 cm^{-1}) depicts perturbations of the vibrational modes of the C-H bond
33
34 evidential to changes in the acyl chain, while the intensity of other bands (1090
35
36 cm^{-1} , 1130 cm^{-1}) is sensitive to intramolecular changes along the acyl chain,
37
38 leading to a *gauche:trans* isomerization. In addition, changes on the head-group
39
40 (715 cm^{-1}) in the carbonyl region can also be followed by Raman Spectroscopy.
41
42
43 Raman spectroscopy allows to calculate ΔS and ΔH through Van't Hoff equations.
44
45
46 All this valuable information can not only confirm DSC data but can give a lot of
47
48 information on the specific interactions of the drug with lipid bilayers. Such detail
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 information is missing from DSC experiments. For example, great difference (7-8
4
5 cm^{-1}) of the choline band between the gel to liquid crystalline phase is evident that
6
7
8 drug is associated with polar segment and exerting electrostatic interactions.
9
10 [2,19,20].

11
12 A complementary technique and valuable for studying the effect of interdigitation
13
14 is x-ray diffraction. X-ray diffraction is a very useful and direct method for
15
16 characterizing materials having periodicity in their structures. Lipid bilayers can
17
18 be packed into a stack of lamellae which give coherent Bragg-like reflections.
19
20 Thus, information can be obtained about their structures and about the effects of
21
22 drugs on the bilayers structure. The periodicity is expressed by the term d-spacing.
23
24 Interdigitation effects cause decrease of d-spacing. Therefore, comparison of d-
25
26 spacing between phospholipid bilayers containing the drug molecule with bilayers
27
28 absent of drug molecules give information on the interdigitation effect of drug
29
30 molecules [21-27].
31
32
33
34
35
36
37
38
39

40 **Materials and Methods**

41 **Materials**

42
43 Phospholipids have been purchased from Avanti Lipids. Anesthetic steroids
44
45 alphaxalone (5α -pregnan-16-en-3 α -ol-11,20-dione); and Δ^{16} -alphaxalone, (5α -
46
47 pregn-16-en-3 α -ol-11,20-dione); were kindly donated by Glaxo Research. The rest
48
49 of the steroids as well as cholesterol were obtained from Sigma, St Louis, MO.
50
51 Losartan was kindly donated by Merck. Vinblastine, dimethyl
52
53 (2 β ,3 β ,4 β ,5 α ,12 β ,19 α)- 15-[(5S,9S)- 5-ethyl- 5-hydroxy- 9-(methoxycarbonyl)-
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1,4,5,6,7,8,9,10-octahydro-2*H*-3,7-methanoazacycloundecino [5,4-*b*]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3,4-dicarboxylate) and Vincristine, methyl (1*R*,9*R*,10*S*,11*R*,12*R*,19*R*)-11-(acetyloxy)-12-ethyl-4-[(13*S*,15*S*,17*S*)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca- 4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca- have been purchased from Sigma Aldrich. All chemicals were used with no further purification.

Methods

Differential Scanning Calorimetry

Thermal scans were carried out using Perkin-Elmer DSC-7 calorimeter (Norwalk, CT). All samples were scanned from 10 to 60 °C until identical thermograms were obtained using a scanning rate of 2.5 °C/min. The temperature scale of the calorimeter was calibrated using indium ($T_m = 156.6$ °C) and DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) bilayers ($T_m = 41.2$ °C). The following diagnostic parameters were used for the study of drug to membrane interactions: T_m (maximum of the recorded heat capacity), T_{onset} (the starting temperature of the phase transition) and $T_{m1/2}$ (the half-height width of the phase transition). An empty pan for the base line and a sample containing double distilled water were run for the temperature range of 10 – 60 °C as a reference for the background. This background was subtracted from each thermal scan of the samples. The area under the observed peak represents the enthalpy change during the transition (ΔH). The mean values of ΔH of three identical scans were tabulated.

Raman spectroscopy

A portion of the prepared samples (~40mg) was used for the Raman experiments. The Raman spectra were obtained at 4 cm⁻¹ resolution from 100 – 3500 cm⁻¹ with an interval of 2 cm⁻¹ using a Perkin – Elmer (Shelton, CT) NIR FT-spectrometer (Spectrum GX II) equipped with a charge – coupled device detector. The measurements were performed at a temperature range of 25 – 50 °C. The temperature was kept constant for 1 hour by using a temperature controller from Ventacon (England). The laser power (an Nd:YAG excited at 1064 nm) was kept constant at 400 mW during the measurements. 1500 scns were accumulated, and back – scattering light was collected.

X-ray diffraction

For the X-ray diffraction experiments the preparations were deposited on an aluminum foil, dried at 35 °C and mounted on a curved glass holder. Small angle X-ray scattering (SAXS) experiments were performed on an Elliott GX18 generator (Marconi Avionics), equipped with a camera utilizing a single vertical Franks' mirror. Small angle x-ray diffraction patterns were collected using a Braun position-sensitive proportional counting (PSPS) gas flow detector (Innovative Technology, South Hamilton, MA). During the experiment, we used a helium path for a specimen-to-detector distance of 130 mm and collected the diffraction data with digital accumulations of 1·10⁶ to 2·10⁶ counts to improve the signal-to-noise ratio. Data was transferred to a VAX computer system and the

intensities were integrated from the computer plots by calculating the area under the diffraction peaks.

Molecular Dynamics Simulations

MD simulations have been carried in order to scan the interdigitation effect at the MMK3/DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) system. The system includes 6 MMK3 and 128 DMPC lipids. DMPC lipid bilayer for the MD simulations was obtained from Dr. M. Karttunen's web page [28] (128 DMPC lipids and 3655 water molecules after 20 ns) [29,30]. The MD simulations were performed with GROMACS 3.3.1 software package [31] using GROMOS96 force field [32]. Simulations were run in the NPT ensemble at 315 K and 1 bar with periodic boundary conditions. During equilibration, the Berendsen barostat and thermostat algorithms were applied [33]. Electrostatic interactions were calculated using the particle mesh Ewald method [34]. Cutoff distances for the calculation of Coulomb and van der Waals interactions were 1.0 and 1.4 nm, respectively. Prior to the dynamics simulation, energy minimization was applied to the full system without constraints using the steepest descent integrator for 2000 steps with the initial step size of 0.01 Å (the minimization tolerance was set to 1000 kJ/(mol.nm)). The system was then equilibrated via 250 ps simulations with a time step of 2 fs. Finally, a 2.0 ns simulation was performed at 315 K and 1 bar with a time step of 2 fs using Berendsen thermostat and Parrinello-Rahman barostat algorithms [35]. All bonds were constrained using the LINCS algorithm [36]. Visualization of the dynamics trajectories was performed with the VMD software package. [37] Origin 6.0 program [38] was used for the plots.

Results and Discussion

We have previously studied AT₁ antagonists, antihypertensive drug molecules that started to be developed two decades ago and known to exert their action in the transmembrane region of lipid bilayers. Due to their amphipathic property, are expected to act first in the lipid bilayer and then to diffuse to the active site of the receptor. An approach of combining various physical chemical methodologies such as Differential Scanning Calorimetry, Raman spectroscopy and x-ray diffraction is used to investigate their thermal and dynamic properties in lipid bilayers. Our studies depicted that when these molecules are incorporated in the lipid bilayers induce partial interdigitation. In particular: (a) they cause increase of ΔH as it is depicted from the integration of the phase transition in calorimetric results; (b) they lower the *gauche:trans* ratio and increase the intermolecular interactions between opposite aliphatic chains as it is shown in Raman Spectroscopy; (c) they are localized at the interface, an ideal topography in the lipid bilayers to form voids in the head-group region and induce partial interdigitation between the lipid layers. This information is derived using a combination of DSC, solid state NMR, Raman spectroscopy, and x-ray diffraction as well as Molecular Dynamics experiments. This effect is related to their drug efficacy as it is reported in our previous study comparing the interdigitation effect in DPPC bilayers using a commercial potent AT₁ antagonist losartan and a

1
2
3 synthetic derivative of low activity MMK3 ((5S)-1-benzylo-5-(1H-benzimidazol-
4 1-ylomethyl)-2-pyrrolidinone) [19,22,39].
5
6

7
8 In the present study we wish to show additional experimental evidence that
9
10 confirms our previous approach for detecting the formation of interdigitation. For
11
12 that reason we used two classes of molecules, namely anesthetic steroids and
13
14 vinca alkaloids. Anesthetic steroids are expected to be molecules that are not
15
16 exerting interdigitation effect in phospholipid bilayers since are extensive
17
18 molecules and they are expected to be incorporated in the same way as cholesterol
19
20 by influencing mainly the alkyl chains of the bilayers [40-43]. Contrarily,
21
22 vinblastine and vincristine which are vinca alkaloids are expected to show
23
24 interdigitation effect in phospholipid bilayers because their amphiphilic and bulky
25
26 properties.
27
28
29
30

31
32 We have studied the effect of the anesthetic steroid alphaxalone and its inactive
33
34 congener Δ^{16} -alphaxalone using DSC as a diagnostic technique [Table 1]. Thus,
35
36 ΔH of the main transition was calculated for the two preparations. The value
37
38 obtained was the mean value for three calculations and did not differ by more than
39
40 5%. As phospholipids for our study we have used: (a)
41
42 dipalmitoylphosphatidylcholine, a widely used phospholipid, that it contains
43
44 symmetric and saturated alkyl chains; (b) dipalmitoylphosphatidylethanolamine
45
46 that differs from dipalmitoylphosphatidylcholine in the head-group. It contains
47
48 ethanolamine instead of choline; (c) dioleoylphosphatidylcholine, a phospholipid
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 that it contains a double bond in the alkyl chain between 9 and 10 carbons,
4
5 characterized by a very low phase transition.
6
7

8 The DSC results on ΔH of the pair of anesthetic steroids at the three different
9
10 phospholipids are shown in [Figure 3](#). In all cases the two anesthetic steroids cause
11
12 decrease of ΔH although not very significant at the concentration of $x=0.20$ molar
13
14 ratio. Thus, these results do not suggest an interdigitation effect of these steroids
15
16 on the phospholipid bilayers under study.
17
18

19
20 Addition of cholesterol in these phospholipids caused a decrease of ΔH in a
21
22 concentration dependent similar to cholesterol effect. The presence of alphaxalone
23
24 or Δ^{16} -alphaxalone in phospholipid bilayers containing cholesterol decreased
25
26 further the enthalpy change [[Figure 4](#)]. When the phase transition was
27
28 significantly broad, no ΔH could be calculated, that is the reason for some values
29
30 are missing.
31
32

33
34 A confirmation of these results was achieved for a series of anesthetic steroids
35
36 molecules in DPPC bilayers. All the anesthetic steroids run having a wide range of
37
38 biological activity caused decrease or no change of ΔH [[Table 1, Figure 5](#)].
39
40

41 We have run x-ray diffraction experiments in dimyristoylphosphatidylcholine
42
43 bilayers for alphaxalone and Δ^{16} -alphaxalone in absence [[Figure 6a](#)] and presence
44
45 of cholesterol [[Figure 6b](#)]. We observed that, for the DMPC preparations
46
47 containing Δ^{16} -alphaxalone, the d-spacing in the liquid crystalline phase was
48
49 identical to that of the control DMPC preparation, whereas the d-spacing of
50
51
52
53
54
55
56
57
58
59
60

1
2
3 DMPC containing the anesthetic steroid alphaxalone was always smaller by 1.5 Å
4
5 due to its more liquid state at the corresponding temperatures. Addition of Δ^{16} -
6
7
8 alphaxalone in DPPC preparation containing cholesterol ($x=0.15$) again did not
9
10 change the d-spacing. Addition of the active analog as it is expected reduced it
11
12 insignificantly.
13

14
15 Also, the interactions between vinca alkaloids vinblastine and vincristine with
16
17 DPPC bilayers were examined at $x=0.17$ molar ratio of the drugs. The influence of
18
19 these molecules on ΔH values are shown in Figure 7, and are compared with those
20
21 of AT_1 antagonist losartan. The presence of vinca alkaloid incorporated in DPPC
22
23 bilayers shows *ca* 17% increase in ΔH values, like that caused by losartan which is
24
25 21%. This increase is an evidence of the formation of the partial interdigitated
26
27 phase in the gel phase (P_{β}). Addition of $x=0.10$ molar ratio of cholesterol
28
29 decreases the value of ΔH *ca* 35% as it is expected in all cases, because
30
31 cholesterol is a known molecule which disturbs the creation of interdigitation
32
33 effect [Figure 7].
34
35
36
37
38

39 For a more detailed analysis of the formation of the interdigitation, it is applied
40
41 Raman spectroscopy on these samples for monitoring the *gauche:trans*
42
43 isomerization and the intermolecular interactions between opposite acyl chains.
44
45 We have calculated the Raman intensity ratio I_{1090}/I_{1130} which constitutes a direct
46
47 measurement of *gauche* and *trans* population and Raman intensity ratio I_{2850}/I_{2880}
48
49 which reflects the intermolecular interactions. In addition, changes in the head
50
51
52
53
54
55
56
57
58
59
60

1
2
3 group region were obtained by analysis of the C – N band. The obtained results
4
5 are shown in **Figure 8a-d**.

6
7
8 **Figure 8a** represents the peak height intensity ratio I_{2850}/I_{2880} for DPPC bilayers
9
10 containing either vinblastine or vincristine or Losartan at $x=0.17$ molar ratio. The
11
12 lower the ratio is, the greater the interactions between the opposite alkyl chains. In
13
14 general terms, the value of the ratio I_{2850}/I_{2880} in all temperatures of loaded DPPC
15
16 samples is lower than the correlated value of unloaded DPPC sample, an
17
18 observation which reveals the formation of interdigitation in both gel and liquid
19
20 phase. The addition of $x=0.10$ molar ratio cholesterol in the previous samples
21
22 increases the value of this ratio in gel phase, indicating that cholesterol prevents
23
24 the formation of interdigitation at temperatures below melting points. Whereas, at
25
26 temperatures above melting points there is no affect on these values,
27
28 demonstrating that the presence of an interdigitated liquid phase is not affected by
29
30 cholesterol [Figure 8b].
31
32
33
34
35

36 Concerning the intramolecular interactions, it was studied the peak high intensity
37
38 ratio I_{1090}/I_{1130} , which reflects the *gauche:trans* isomerisation. **Figure 8c** shows
39
40 that the presence of vinblastine or vincristine at $x=0.17$ in DPPC bilayers
41
42 decreases the value of this ratio in liquid phase in the same pattern as losartan,
43
44 compared with unloaded DPPC's values, reflecting the presence of interdigitation
45
46 phenomenon in liquid phase. These results show again the similar behaviour of
47
48 these drugs in inducing interdigitation at the liquid phase.
49
50
51
52
53
54
55

1
2
3 **Figure 8d** presents the shift of the band C – N, which reveals the electrostatic
4 interactions between the examined molecules with the interface of the bilayers. In
5
6 unloaded DPPC this band shifts at about 2 cm^{-1} , while in the cases of vinblastine
7
8 and vincristine at about 6 cm^{-1} and losartan's at about 8 cm^{-1} . These results show
9
10 that these molecules affect in a similar way the head-group of the DPPC bilayers.
11
12 It appears that DSC can be a predictive methodology for the partial
13
14 interdigitation effect. DSC results for the molecules losartan, vinblastine and
15
16 vincristine published to exert interdigitation effect in DPPC bilayers are shown
17
18 to increase ΔH in the absence of cholesterol. When cholesterol is presence they
19
20 oppose the effect of the decrease of ΔH observed by cholesterol [**Figure 7**]. More
21
22 detail experiments are under progress for providing more evidence to the above
23
24 obtained results.
25
26
27
28
29
30
31

32 MD Simulations have been applied at *DMPC* bilayers including *MMK3*. In order
33
34 to see the effects of molecules to interdigitation clearly, the six *MMK3*
35
36 molecules (instead of one) are inserted in *DMPC* bilayers and are shown in
37
38 Figure 9. Interdigitation has been scanned with the change of coordinates at
39
40 head group oxygens. Specifically, change of distance at z-axis of oxygen atom at
41
42 head group (labeled as O11) has been measured throughout the simulations
43
44 (**Figure 10**). Representative figure for DMP-7 at layer-A and DMP-55 at layer B
45
46 shows clearly that oxygen atom position at DMP-7 was increased (+z axis about
47
48 2 \AA) whereas corresponding oxygen atom position at DMP-55 was decreased (-z
49
50 axis about 6 \AA). This analysis has been repeated for all other lipids used in the
51
52 simulations. Results showed that, the observation for DMP-7 and DMP-55 is
53
54 similar for other *DMPC* lipids at layers A and B (Figure 11).
55
56
57
58
59
60

1
2
3 A statistical analysis for all DMPC lipids at layers A and B used in MD
4 simulations was performed. Results showed that oxygen atom (O11) has been
5 shifted 1.96 Å in +z-axis (average value out of 44 DMPC) at layer A and 6.86 Å
6 in -z axis (average value out of 39 DMPC) at layer B. Thus ~8.8 Å interdigitation
7 has been occurred.
8
9

10
11
12
13
14 While experiments can provide a fairly complete description of an interdigitation,
15 such experiments usually require a great deal of effort and it is difficult to be
16 performed routinely. Similar information on interdigitation may be obtained more
17 easily using molecular modeling techniques such as MD simulations, which have
18 become feasible during the last decade attributed to the rapid growth in
19 computational power. To our knowledge, this is the first attempt using *in silico*
20 techniques on examination of partial interdigitation of lipid bilayers. The obtained
21 computational results are very encouraging and they may open a new avenue for
22 entire investigation of interdigitation. Thus, questions such as which kind of
23 molecules enhance the interdigitation and which ones not, and how cholesterol
24 molecules at lipid bilayers effect the interdigitation can be successfully addressed.
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Conclusions:** We have shown that DSC, a simple thermodynamic technique can
39 be predictive for showing partial interdigitation. The thermodynamic parameter
40 used for the prediction of partial interdigitation is the increase of enthalpy change
41 when the additive drug is incorporated in lipid bilayers. Confirmation of the
42 predictive power of DSC can be realized using a combination of x-ray diffraction
43 experiments along with Raman spectroscopy.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We have shown that for AT1 antagonists, the increase of ΔH is accompanied by d-
4 spacing decrease and increase of *trans:gauche* isomerization. Anesthetic steroids
5
6 that do not show increase of ΔH and they have been shown to not decrease d-
7 spacing by small x-ray diffraction. Thus, in this case, x-ray results are in
8
9 agreement with DSC data. Vinca alkaloids vinblastine and vincristine have shown
10
11 to increase ΔH in DSC experiments. Indeed, Raman spectra show increase of
12
13 *trans:gauche* ratio and preliminary small angle x-ray results show that these vinca
14
15 alkaloids decrease the d-spacing values. In conclusion, all three experimental
16
17 methodologies can be used as complementary to reveal partial interdigitation.
18
19

20
21
22 Molecular Dynamics can be applied for observing the partial interdigitation
23
24 eminent in the experimental results used in the above mentioned methodologies.
25
26 Thus, a direct measurement of the displacement of the terminal alkyl segment due
27
28 to the presence of drug molecule can be used. These theoretical calculations will
29
30 make faster the understanding of the stereoelectronic requirements for partial
31
32 interdigitation.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Slater, J. L.; and Huang, C. H. *Prog Lipid Res* 1988, 27, 325-359.
2. O' Leary, T. J.; Levin, I. W. *Biochim Biophys Acta* 1984, 776 (2), 185 – 189.
3. O' Leary, T. J.; Ross, P. D.; Levin, I. W. *Biophys J* 1986, 50 (6), 1053 – 1059.
4. Auger, M.; Smith, I. C. P.; Jarrell, H. C. *Biochim Biophys Acta* 1989, 981 (2), 351 – 357.
5. Löbbecke, L.; Cevc, G. *Biochim Biophys Acta* 1995, 1237 (1), 59 – 69.
6. Koukoulitsa, C.; Kyrikou, I.; Demetzos, C.; Mavromoustakos, T. *Chem Phys Lipids* 2006, 144 (1), 85 – 95.
7. Cunningham, B. A.; Lis, L. J. *Biochim Biophys Acta* 1986, 861 (2), 237 – 242.
8. Maswadeh, H.; Demetzos, C.; Daliani, I.; Kyrikou, I.; Mavromoustakos, T.; Tsortos, A.; Nounesis, G. *Biochim Biophys Acta* 2002, 1567, 49 – 55.
9. Kyrikou, I.; Daliani, I.; Mavromoustakos, T.; Maswadeh, H.; Demetzos, C.; Xatziantoniou, S.; Giatrellis, S.; Nounesis, G. *Biochim Biophys Acta* 2004, 1661 (1), 1 – 8.
10. McIntosh, T. J.; McDaniel, R. V.; Simon, S.A. *Biochim. Biophys. Acta* 1983, 731 (1), 109 – 114.
11. Demetzos, C.; Matsingou, C. *Chem Phys Lipids* 2007, 145 (1), 45 – 62.
12. Nerdal, W.; Gundersen, S. A.; Thorsen, V.; Heiland, H.; Holmen, H. *Biochim Biophys Acta* 2000, 1464, 165 – 175.
13. Hao, Y.; Xu, Y.; Chen, J.; Huang, F. *Biochim Biochem Biophys Res Commun* 1998, 245, 439 – 442.
14. Gjerde, A. U.; Holmsen, H.; Nerdal, W. *Biochim Biophys Acta* 2004, 1683, 28 – 37.

15. Cao, A.; Brachet, E. H.; Azize, B.; Taillanlier, E.; Perret, G. *Chem Phys Lipids* 1991, 58, 225 – 232.
16. Banuelos, S.; Arrono, J. L.; Cavaves, R. J. M.; Ferragut, J. A.; Muga, A. *Eur J Biochem* 1993, 213, 1269 – 1275.
17. Attal, Y.; Co, X. A.; Perret, G.; Tailandier, E. *Chem Pharm Bull* 1997, 45 (1), 1317 – 1322.
18. Nguyen, T. S.; Weers, P. M. M.; Raussens, V.; Whang, Z.; Ren, G.; Sulehek, T.; Hoepflich, P. D.; Ryan, R. O. *Biophys Biochim Acta* 2008, 1778, 303 – 312.
19. Fotakis, C.; Christodouleas, D.; Chatzigeorgiou, P.; Zervou, M.; Benetis, N. P.; Viras, K.; Mavromoustakos, T. *Biophys J* 2009, 96, 2227 – 2236.
20. Kyrikou, I.; Xadjikakou, S.; Kovala-Demertzi, D.; Viras, K.; Mavromoustakos, T. *Chem Phys Lipids* 2004, 132, 157 – 169.
21. Mavromoustakos, T.; Papahadjis, D.; Laggner, P. *Biochim Biophys Acta* 2001, 1512 (2), 183 – 190.
22. Mavromoustakos, T.; Yang, D. P.; Broderick, W.; Fournier, D.; Herbette, L. G.; Makriyannis, A. *Pharmacol Biochem Be* 1991, 40, 547 - 552.
23. Yang, D. P.; Mavromoustakos, T.; Beshah, K.; Makriyannis, A. *Biochim Biophys Acta* 1992, 1103, 25 – 36.
24. Yang, D. P.; Mavromoustakos, T.; Makriyannis, A. *Life Sci* 1993, 53, 117 – 122.
25. Mavromoustakos, T.; Yang, D. P.; Charalambous, A.; Herbette, L. G.; Makriyannis, A. *Biochim Biophys Acta* 1990, 1024, 336 – 344.
26. Mavromoustakos, T.; Yang, D. P.; Makriyannis, A. *Biochim Biophys Acta* 1995, 1237, 183 – 188.
27. Rappolt, M.; Laggner, P.; Pabst, G. 2004. In: *Recent Res. Devel. Biophys.* Vol 3, Part II, Transworld Research Network, editor S.D. Pandalai, Trivandrum, 363.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. SoftSimu, Dr. Mikko Karttunen web page
<http://www.apmaths.uwo.ca/~mkarttu/downloads.shtml> (accessed Jan 8, 2009).
 29. Patra, M.; Karttunen, M.; Hyvonen, M.; Falck, E.; Lindqvist, P.; Vattulainen, I. *Biophysical Journal* 2003, 84, 3636-3645.
 30. Patra, M.; Karttunen, M.; Hyvonen, M.; Falck, E.; Lindqvist, P. *J. Am. Chem. Soc.* 2004, 126, 4485- 4494.
 31. van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A. E.; Berendsen, H. J. J. *J. Comput. Chem.* 2005, 26, 1701-1717.
 32. Van Gunsteren, W. F.; Billeter, S. R.; Eising, A. A.; Hunenberger, P. H.; Kruger, P.; Mark, A. E.; Scott, W. R. P.; Tironi, I. G. *Biomolecular Simulation: the GROMOS96 Manual and User Guide*; Vdf Hochschulverlag AG an der ETH Zurich, Zurich. 1996.
 33. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. *J. Chem. Phys.* 1984, 81, 3684-3690.
 34. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. *J. Chem. Phys.* 1995, 103, 8577-8593.
 35. Parrinello, M.; Rahman, A. *J. Appl. Phys.* 1981, 52, 7182-7190.
 36. Hess, B.; Bekker, H.; Berendsen, H.J.C.; Fraaije, J.G.E.M. *J. Comput. Chem.* 1997, 18, 1463-1472.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
37. Humphrey, W.; Dalke, A.; Schulten, K. J. *Molec. Graphics. VMD: visual molecular dynamics*. 1996, 14, 33-38.
38. Microcal products. <http://www.microcal.com> (accessed Jan 8, 2009).
39. Zoumpoulakis, P.; Daliani, I.; Zervou, M.; Kyrikou, I.; Siapi, E.; Lamprinidis, G.; Mikros, E.; Mavromoustakos, T. *Chem Phys Lipids* 2003, 125, 13 – 25.
40. Mavromoustakos, T.; Yang, D. P.; Makriyannis, A. *Biochim Biophys Acta* 1994, 1194 (1), 69 – 74.
41. Mavromoustakos, T.; Yang, D. P.; Makriyannis, A. *Biochim Biophys Acta* 1995, 1239 (2), 257 – 264.
42. Mavromoustakos, T.; Theodoropoulou, E.; Yang, D. P. *Biochim Biophys Acta* 1997, 1328 (1), 65 – 73.
43. Makriyannis, A.; Yang, D. P.; Mavromoustakos, T. The molecular features of membrane perturbation by anaesthetic steroids: a study using differential scanning calorimetry, small angle x-ray diffraction and solid state ^2H "Steroids and Neuronal Activity" Ciba Foundation Symp. No. 153. J. Wiley London 172-189 (1990).